CCL21-CCR7 blockade prevents neuroinflammation and degeneration in Parkinson’s disease models

CCL21-CCR7 blockade prevents neuroinflammation and degeneration in Parkinson’s disease models

Abstract Parkinson’s disease (PD) is a progressive degenerative disease of the central nervous system associated with neuroinflammation and microglial cell activation. Chemokine signaling regulates neuron-glia communication and triggers a microglial inflammatory profile. Herein, we identified the ne...

Full description

Saved in:
Bibliographic Details
Main Authors: Felipe Saceanu Leser, Flavio de Souza Júnyor, Iohanna Bianca Pagnoncelli, Anna Beatriz Delgado, Isabelle Medeiros, Ana Clara Campanelli Nóbrega, Brenda da Silva Andrade, Maiara Nascimento de Lima, Nícolas Emanoel da Silva, Laurent Jacob, Kevin Boyé, Luiz Henrique Medeiros Geraldo, Alessandra Mendonça Teles de Souza, Tatiana Maron-Gutierrez, Hugo Castro-Faria-Neto, Cristian Follmer, Carolina Braga, Gilda Angela Neves, Anne Eichmann, Luciana Ferreira Romão, Flavia Regina Souza Lima
Format: Article
Language:English
Published: BMC 2025-02-01
Series:Journal of Neuroinflammation
Subjects:
Parkinson`s disease
Neuroinflammation
Microglia
Chemokine signaling
CCL21-CCR7 pathway
DOPAL
Online Access:https://doi.org/10.1186/s12974-024-03318-x
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Parkinson’s disease (PD) is a progressive degenerative disease of the central nervous system associated with neuroinflammation and microglial cell activation. Chemokine signaling regulates neuron-glia communication and triggers a microglial inflammatory profile. Herein, we identified the neuronal chemokine CCL21 as a major cause of microglial cell imbalance through the CCR7 receptor pathway with therapeutic implications for PD. In humans, we found that CCL21 transcript expression was increased in dopaminergic neurons (DANs) of the substantia nigra in PD patients. CCL21 and CCR7 expressions were spatially associated with brain regional vulnerability to synucleinopathies, as well as with the expression of microglial activation, neuroinflammation, and degeneration-related genes. Also, in mouse models of PD, we showed that CCL21 was overexpressed in DANs in vivo and in vitro. Mechanistically, neuronal CCL21 was shown to regulate microglial cell migration, proliferation, and activation in a CCR7-dependent manner through both canonical (PI3K/AKT) and non-canonical (ERK1/2/JNK) signaling pathways. Finally, we demonstrated that navarixin, a clinically relevant chemokine inhibitor with high affinity for the CCR7 receptor, could block CCL21 effects on microglia and prevent neurodegeneration and behavioral deficits in two mouse models of PD induced with either α-synuclein oligomers (αSynO) or 3,4-dihydroxyphenylacetaldehyde (DOPAL). Altogether, our data indicate that navarixin blocks CCL21/CCR7-mediated neuron-microglia communication and could be used as a therapeutic strategy against PD. Graphical Abstract
ISSN:1742-2094

Similar Items